Physician profile
John B Cage
NPI 1003819277
$3,997.14
in general payments reported to CMS, 2019-2025
20 companies · $62.96 in 2025
The $62.96 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $503 · 2021: $380 · 2022: $595 · 2023: $1,108 · 2024: $494 · 2025: $62.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,664.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $794.96 | 2021-2023 | Watchman Access System, Watchman Flx |
| Abbott Laboratories | $544.04 | 2020-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Amgen INC. | $447.82 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $394.95 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $305.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $300.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $208.80 | 2021-2023 | Verquvo, Belsomra, Lagevrio |
| Novo Nordisk INC | $177.57 | 2020-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.15 | 2019-2023 | Jardiance |
| Pfizer INC. | $168.56 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $101.63 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $101.52 | 2019-2024 | Evkeeza |
| E.R. Squibb & Sons, L.L.C. | $62.80 | 2019-2024 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $45.01 | 2024 | |
| Alnylam Pharmaceuticals INC. | $42.02 | 2024-2025 | Onpattro |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $39.92 | 2023 | Inpefa |
| Zealand Pharma US, INC. | $26.42 | 2022 | |
| Recor Medical INC | $22.32 | 2024 | Paradise Renal Denervation System |
| Kiniksa Pharmaceuticals International, Plc | $19.07 | 2024 | Arcalyst |
| Xeris Pharmaceuticals, INC. | $16.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.